Alphamab Oncology
Alphamab Oncology, a leading biopharmaceutical company headquartered in China, is at the forefront of innovative cancer therapies. Founded in 2016, the company has rapidly established itself in the oncology sector, focusing on the research, development, and commercialisation of monoclonal antibodies and other biologics. With a strong presence in both domestic and international markets, Alphamab Oncology has achieved significant milestones, including the successful development of its proprietary drug candidates. Their core products, distinguished by their unique mechanisms of action, aim to address unmet medical needs in cancer treatment. Recognised for its commitment to advancing oncology solutions, Alphamab Oncology continues to strengthen its market position through strategic partnerships and a robust pipeline, making it a notable player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Alphamab Oncology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alphamab Oncology's score of 19 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alphamab Oncology's reported carbon emissions
In 2023, Alphamab Oncology reported total carbon emissions of approximately 12,760,810 kg CO2e, with Scope 1 emissions at about 3,969,510 kg CO2e and Scope 2 emissions at around 8,791,300 kg CO2e. This marked a significant reduction from previous years, particularly from 2021, when total emissions were approximately 9,920,390 kg CO2e. The company has shown a consistent commitment to monitoring and reporting its emissions, with disclosed data for Scope 1 and Scope 2 emissions across multiple years. However, there are currently no specific reduction targets or climate pledges outlined in their initiatives. Alphamab's emissions data reflects its operational impact and highlights the importance of ongoing efforts in carbon management within the biotechnology sector. The company continues to focus on transparency in its emissions reporting, which is crucial for stakeholders and aligns with industry standards for climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 75,810 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 798,260 | 00,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alphamab Oncology is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
